Ignite Creation Date:
2025-12-25 @ 2:19 AM
Ignite Modification Date:
2025-12-26 @ 4:59 PM
Study NCT ID:
NCT01505634
Status:
COMPLETED
Last Update Posted:
2019-05-24
First Post:
2012-01-04
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Safety, Tolerability, and Efficacy of MK-7655 (Relebactam) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone for Treating Complicated Urinary Tract Infection (cUTI) (MK-7655-003)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2012-05-16
Start Date Type:
ACTUAL
Primary Completion Date:
2015-07-28
Primary Completion Date Type:
ACTUAL
Completion Date:
2015-07-28
Completion Date Type:
ACTUAL
First Submit Date:
2012-01-04
First Submit QC Date:
None
Study First Post Date:
2012-01-06
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2019-04-26
Results First Submit QC Date:
None
Results First Post Date:
2019-05-24
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2019-04-26
Last Update Post Date:
2019-05-24
Last Update Post Date Type:
ACTUAL